SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented at UEGW demonstrating robust preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback